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Abstract 
Urinary tract infections are the second common reason of medical 
consultations and antibiotics prescription. Escherichia coli is known to cause 
most urinary tract infections. The aim of this study was to characterize and 
determine the antibiotic resistance profile of E. coli extended-spectrum β-
lactamases (ESBL) producer strains isolated from urine samples. The urine 
samples collected came from hospitalized and non-hospitalized patient 
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referred to Hubert Koutoukou Manga (HKM), National and University 
Hospital Center (Cotonou, Benin). The resistance to antibiotics was 
determined according to the disk diffusion method. The production of 
penicillinase and ESBLs was researched respectively by the acidimetric test 
and double disk synergy method. The presences of genes encoding β-
lactamases were detected by Polymerase Chain Reaction (PCR). Our data 
revealed that 60 % of E. coli strains (101) were isolated from female patients. 
Also, 69.31 % of the strains were isolated from non-hospitalized patients. The 
high resistance levels were recorded with amoxicillin (96.04 %) and 
amoxicillin + clavulanic acid (66.34 %). Twenty percent (20%) of strains 
were ESBLs. Among ESBLs strains, 70% comes from non-hospitalized 
patients. Eighty percent of E. coli strains produced penicillinase among which 
25 % were ESBL producers. All the ESBL producers strains carried blaTEM 
gene whereas only 30 % carried the blaSHV gene. This study updates the data 
on the prevalence to antibiotic resistance of E. coli ESBL producers strains 
for better management of urinary tract infections.  
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Introduction 
Infectious diseases are world widespread causing over 50 000 deaths 
daily (Ahmad et Beg, 2001). Many bacteria, such as Escherichia coli, were 
involved in those infections. E. coli, part of the human commensal Flore, is 
known to be the first bacteria to colonize humans gut. Indeed, E. coli 
belonging to the family of Enterobacteriaceae is an important opportunist 
human pathogen associated with infections such as urinary tract, surgical site, 
skin, soft tissues, bacteremia, and pneumonia infections (Pitout, 2012; 
Carvalho et al., 2012). Among those infections, urinary tract infections are 
considered as a public health problem (Fatna et al., 2009) because the urine 
of healthy person must be exempt of any microorganism (Foxman, 2002). 
Thus, the identification of the cause and severity of the urinary tract infection 
are usually established through biochemical and microbiological analysis of 
urines. Urinary tract infections having E. coli as etiological agent are common 
infections with an estimated annual global incidence of at least 250 million 
cases (Chauhan et al., 2015). 
To treat infections induced by E. coli strains, antibiotics such as those 
β-lactam groups are currently used. This group includes the penicillin’s 
cephalosporins, carbapenems, clavams and monobactams (Singleton, 1999). 
Often, the β-lactam ring is cleaved by a bacterial enzyme named β-lactamase 
(Edwards et Greenwood, 1992). But population density, uncontrolled use of 
antibiotics, lack of clean water supply and lack of proper treatment for sewage 
has resulted in the selection of multidrug resistant bacterial strains. This 
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becomes a serious challenge for drug prescription in infectious diseases 
management (Carlet et al., 2012). For example, in developed countries, it was 
reported that the economic and human damage caused by antibiotic-resistance 
is increasing at an alarming rate (Bush et al., 2011). Infections with 
multidrug-resistant organisms have linked with poorer clinical outcomes and 
prolonged hospitalization on average compared to infectionss with 
susceptible pathogens (Maina et al., 2017). 
In hospital area, the extended spectrum β-lactamases (ESBL) strains 
are one of the barriers to efficient treatment of E. coli infections (Lucet et al., 
1996). The selection of E. coli strains producing ESBL is increased by the 
large prescription of third cephalosporins generation. We should notice that 
ESBL are enzymes that confer resistance to aztreonam, cefotaxime, 
ceftazidime, and like to relate oxyimino-𝛽-lactams as well as other penicillin 
and cephalosporins (Bush et al., 1995). The most common mechanism of the 
resistance to β-lactam antibiotics is the production of β-lactamase. The genes 
encoding for β-lactam production are generally harbored by plasmids 
(Paterson et Bonomo, 2005). Although there are several type genes encoding 
for ESBL, the first and most founded mutants are blaTEM and blaSHV (Bois et 
al., 1995; Medeiros, 1997). The mutants with those genes can deflect the 
oxyimino group and then induce the resistant to all oxyimino-cephalosporins 
(except 𝛼-methoxy cephalosporins) (Livermore et Woodford, 2006).  
In Benin, few papers report on the urinary tract infection focusing on 
the E. coli strains characterization. To fill this gap, it will be useful to update 
E. coli ESBLs information. Thus, the aim of this study was to characterize 
and determine the antibiotic resistance profile of E. coli ESBL producer 
strains isolated from urine samples.  
 
Material and methods:  
Samples collection 
A total of 979 urines samples were collected from both hospitalized 
patient and non- hospitalized patient referred to National and University 
Hospital Center Hubert Koutoukou Manga (Cotonou, Benin). The urine 
samples collected from January to April 2015. Sample of patient hospitalized 
in the Hospital Center was considered as hospitalized patient. If the patient 
wasn’t hospitalized in Hospital Center, he was considered as no hospitalized 
patient. Among the urine samples sent to the Microbiology laboratory of 
CNHU for analysis, only those that were analyzed for the purpose of 
diagnosing urinary tract infection and whose Escherichia coli strains were 
isolated mainly were taken into account in this study. 
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Isolation and identification of E. coli strains 
The collected samples were cultured on Eosin Methylene Blue (EMB) 
agar (Oxoid, UK) media. On the EMB agar, E. coli gives purple colonies in 
the dark center, semi-convex 2 to 3 mm in diameter and sometimes have a 
metallic sheen After overnight incubation in aerobic condition (18-24 h) at 37 
°C, the colonies suspected to be E. coli were picked and purified for E. coli 
identification according to standard biochemical tests (gram coloration, 
oxidase test and citrate utilization) (Riegel et al., 2005), before a confirmation 
with API 20E (Bio Mérieux, France) gallery.  
 
Antibiotics resistance of isolated strains 
The susceptibility of the isolated E. coli strains to 16 antimicrobial 
agents was evaluated by the disk diffusion method on Mueller-Hinton agar 
according to the French Society for Microbiology guidelines (CASFM, 
2015).  
The antimicrobial agents (BioMérieux, France) used in this study are: 
amoxicillin (30 μg), amoxicillin/clavulanic acid (20/10 μg), cefoxitin (30 μg), 
cefuroxime (30 μg), cefotaxime (30 μg), ceftriaxone (30 μg), imipenem (10 
μg), gentamicin (15 μg), netilmicin (10 μg), chloramphenicol (30 μg), 
nalidixic acid, (30 μg), norfloxacin (5 µg), ofloxacin (5 μg), ciprofloxacin (5 
μg), trimethoprim/sulfamethoxazole (1.25/23.75 μg) and nitrofurantoin (300 
μg). These antibiotics have been chosen because they are the most used in the 
treatment of urinary tract infections au Benin. 
 
Detection of Penicillinase production 
The production of penicillinase was researched on all E. coli strains 
isolated according to tube acidimetric method as describe by Catlin in 1975. 
Benzyl-penicillin (600 mg) was diluted in 400 µL of distilled water before 
adding 300 µL of aqueous phenol red solution (1 %, w/v). The pH of the 
precedent solution was adjusted to 8 with NaOH solution (1 M). The final 1 
mL reaction volume was composed of a young E. coli colonies in suspension 
and about 150 µl of benzyl-penicillin solution. The E. coli ATCC 25922 
strains was used as a control.  The yellow color apparition within one hour 
indicates penicillinase production. 
 
Phenotypic detection of Extended Spectrum β-Lactamase (ESBL) 
production 
The production of Extended Spectrum β-Lactamase was performed on 
the all isolated E. coli strains by the double disk synergy test as described by 
Jarlier et al. (1988). Agar Muller Hinton medium was seeded with bacteria 
suspension (106 CFU /mL). Amoxicillin + clavulanic acid disk was deposited 
in the Centre of agar. About 20 mm away from two disks external, cefotaxime 
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and ceftazidime disks were added. After 18-24 h of incubation at 37 °C, the 
presence of ESBLs was indicated by a champagne cork aspect between the 
central and the external disks. 
 
Genomic detection of genes coding to Extended Spectrum β-Lactamase 
(ESBL) production 
Detection of the ESBL genes encoding blaTEM and blaSHV was 
performed with total DNA. The DNA template was prepared from freshly 
cultured bacterial isolates by suspending 2-3 colonies in 500 μL of molecular 
grade water and then vortexed to get a uniform suspension. Bacterial cells 
were lysed by heating at 95 °C for 10 min. Cellular debris was removed by 
centrifugation at 12,000 rpm for 2 min and the supernatant was directly used 
as DNA template to amplify blaTEM and blaSHV genes by Polymerase Chain 
Reaction (PCR). The PCR amplification was carried out in volume of 30 μl 
containing 5 μL of DNA, 0.5 μM of each primer (F and R), 1.5 mM MgCl2, 
250 μM dNTPs, 1X PCR buffer (Invitrogen) and 1U Taq DNA polymerase 
(Invitrogen). The primer sequences and the generated fragments are presented 
in the table 1.  
Table 1: Primers used to research for genes bla
TEM
 and bla
SHV. 
Genes  Names Sequences  Size (base pairs)  
bla
TEM
 
TEM OT-1-F  5’-TTGGGTGCACGAGTGGGTTA-3’  
465  
TEM OT-2-R  5’-TAATTGTTGCCGGGAAGCTA-3’  
bla
SHV
 
SHV A  5’-CACTCAAGGATGTATTGTG-3’  
885  
SHV B  5’-TTAGCGTTGCCAGTGCTCG-3’  
 
Amplification was carried out on a DNA thermal cycler (Multigene 
Labnet International, Inc.) as follows: i- for blaTEM (initial denaturation 94 °C 
for 5 min followed by 30 cycles 94 °C for 30 s, 52 °C for 30 sec, 72 °C for 1 
min and a final elongation step 10 min at 72 °C) and ii- for blaSHV (initial 
denaturation was performed at 96 °C for 5 min, 30 cycles of 96 °C for 15 s, 
50 °C for 15 sec, 72 °C for 1 min and a final elongation step 10 min at 72 °C). 
The amplicons were visualized by a trans-illuminator (Euromedex, 
Mundosheim, France) after electrophoresis at 150 V for 30 min on an agarose 
gel (1.2 %, w/v) containing ethidium bromide. 
 
Data analysis 
The results of antimicrobial susceptibility tests were interpreted with 
the standards of the French Society of Microbiology. Microsoft Excel 2013 
Spreadsheet has been used for data processing and the statistical analysis was 
conducted using GraphPad Prism 5. The statistical analysis was run at 95 % 
confidence limit; two tailed test and p < 0.05 were considered as significant. 
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Results  
E. coli strains isolated and penicillinase detection 
About 10.32 % of the 979 urine samples analyzed were contaminated 
by E. coli strains. Our data reveals that 60 % of patients with urinary tract 
infection due to E. coli were female. Among the patients with urinary 
infection due E. coli, non-hospitalized patients represented 69.31 %. But the 
difference of proportion between the two groups of patients (hospitalized 
patients and non-hospitalized patients) was significant (p˃0.05). Among the 
eighty E. coli strains (79.21%) producing penicillinase, 54 (67.5%) were 
isolated from non-hospitalized patients. The statistical analysis reveals that 
the presence of E. coli strains producing penicillinase is not function of the 
patient (in or out) origin (p ˃0.05). 
 
Extended Spectrum β-Lactamase (ESBL) production by E. coli strains 
isolated 
The extended-spectrum β-lactamase (ESBL) was produced by 20 % of 
isolated strains. Seventy percent (70 %) of these strains were isolated from 
non-hospitalized patients. Twenty (20) of 80 strains producer of penicillinase 
were ESBL. About 80 % of these ESBL were isolated from non-hospitalized 
patients against 20 % isolated from hospitalized patients. The data indicate 
that no hospitalized patients carried more ESBL than hospitalized patients (p 
<0.05). 
 
Antibiotics resistance of isolated strains 
Our susceptibility test data displays a variability of isolated E. coli 
strains according to tested antibiotic (Table 2). More than 50% of the E. coli 
strains were resistant to new antibiotics (amoxicillin, amoxicillin+clavulanic 
acid, cefuroxime, nalidixic, ciprofloxacin, ofloxacin, norfloxacin, 
chloramphenicol and trimethoprim sulfa). In addition, high resistance was 
observed with amoxicillin (96.75 %) and trimethoprim sulfa (93.37 %), while 
the most effective antibiotic was Imipenem with less than 1 % of resistant 
strains. 
Among E. coli strains, there was a variation of the resistance 
depending on the antibiotic tested considering their ability to produce or not 
penicillinase (Table 2). However, the recorded differences of resistance 
proportions were not significant independently to the tested molecule (p> 
0.05). It should be noted that the high amoxicillin resistance was recorded on 
both penicillinase producing strains (92.96 %) than non-producing (100 %). 
Only strains resistant to imipenem were penicillinase producers and not 
extended spectrum β-lactamases producers. 
The strain’s resistance profile is highly variable   according to 
antibiotics when we consider the extended spectrum β-lactamase production 
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character (p <0.0001). Globally, the highest proportions of the strains resistant 
to β-lactam antibiotics (cefotaxime, amoxicillin, and ceftriaxone) and 
quinolones (ciprofloxacin, norfloxacin and ofloxacin) were observed with the 
strains of ESBL-producing E. coli (Table 2). 
Table 2: Resistance to antibiotics profile of Escherichia coli strains isolated from urinary 
tract infections. 
 Resistance rate (%)  
 EC (n=101) 
EC- ESBL 
+ (n=20) 
EC- ESBL - 
(n=81) 
EC-Péni + 
(n=80) 
EC-Péni - 
(n=21) 
Net 44 100 30 44 50 
NA 69.75 100 64.81 60.61 70 
AMX 96.75 100 93.85 92.96 100 
AMC 67.33 84.21 63.23 74.32 23.07 
FOX 25.58 31.25 21.15 22.41 30 
CTX 32 100 12.86 30.67 35.71 
CXM 53.72 100 43.55 56.52 50 
CIP 51.03 94.74 40 54.28 50 
OFX 67.79 100 59.18 69.09 80 
GM 41.65 84.21 28.78 40.84 42.86 
NOR 60.37 94.12 53.45 64.61 45.45 
IPM 1 0 1.43 1.33 0 
CRO 33 100 14.28 33.33 28.57 
FT 15.15 26.31 13.04 14.67 21.43 
SXT 93.37 100 88.09 86.05 71.43 
C 66.89 66.67 61.4 58.73 77.78 
Amoxicillin (AMX), amoxicillin/clavulanic acid (AMC), cefoxitin (FOX), cefuroxime 
(CXM), cefotaxime (CTX), ceftriaxone (CRO), imipenem (IPM), gentamicin (GM), 
netilmicin (NET), chloramphenicol (C), nalidixic acid, (NA), norfloxacin (NOR), ofloxacin 
(OFX), ciprofloxacin (CIP), trimethoprim/ sulfamethoxazole (SXT) and nitrofurantoin (FT) , 
EC (Echerichia coli strains), EC- ESBL + (ESBLs producer Echerichia coli strains), EC- 
ESBL- ( not ESBLs producer Echerichia coli strains), EC Péni + (Penicillinase producer 
Echerichia coli strains), EC Péni- (not penicillinase producer Echerichia coli strains). 
 
Presence of gene encoding for Extended Spectrum β-Lactamase (ESBL) 
The genes (blaTEM and blaSHV) encoding for ESBL production by E. 
coli strains isolated from urinary tract infections were found in various 
proportions. Thus, our data reveal that all phenotypically ESBL-producer 
strains had the gene blaTEM (Figure 1a) while 30 % of these strains harbored 
the blaSHV gene (Figure 1b).  
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Legend: - lane 1-7: bla
TEM
 positive samples;  
- lane 8: negative control;  
- lane 9, 10, 13 and 14: negative samples bla
SHV
;  
- lane 11, 12 positive samples bla
SHV
;  
- lane L: ladder.  
Figure 1: Agarose gel showing polymerase chain reaction amplified product of bla
TEM
 (a) 
and bla
SHV
 (b) genes. 
Discussion 
We found a prevalence of 10.32 % for the strains of E. coli isolated 
from urine samples collected from both hospitalized patient and non-
hospitalized patient referred to National and University Hospital Center 
Hubert Koutoukou Manga. The frequency of urinary E. coli infections is 
higher in female patients (59.41 %) than in men. The same tendency was 
observed in Morocco though their recorded prevalence (75 %) is higher than 
ours (Fatna et al., 2009). This is explained the small distance of the female 
urethra and the promoting sex on the growth of bacteria in the bladder urethral 
(Beutin et al., 1997). 
The phenotypic detection of Extended Spectrum β-Lactamase (ESBL) 
showed that the prevalence of E. coli ESBL producer isolated from urinary 
tract infections was 20 %.  Majority of those strains (70 %) were isolated from 
non-hospitalized patients. Our results are relatively higher than the 10 % 
isolated from urinary tract infections in developed country such as America 
(Galles et al., 2002). This different observed can be due to the fact that in 
developing countries, the health care system is more organized than low 
incoming countries such as Benin and the use of drugs such as antimicrobials 
under medical prescriptions. Even in developing countries such as Yaoundé 
in Cameroon (Gangoué-Piéboji et al., 2005) and Departmental Hospital 
Center of Zou-Collines in Benin (Ahoyo et al., 2007), a rate of 14.3 % and 22 
% were respectively reported.  Although, our results are similar to those 
reported in North Africa (Winokur et al., 2001). Indeed, the work of Abbassi 
et al. (2010) in Tunisia founded 67.7 % E. coli ESBL from community 
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patients. The Enterobacteriaceae strains producing ESBL were more often 
founded in hospitals (Winokur et al., 2001). But we nowadays mostly 
recorded an increase of E. coli ESBL strains isolated from outpatient (Younes 
et al., 2011; Lonchel et al., 2012). 
Globally, E. coli strains isolated from urinary tract infections were 
highly (96.75 %) resistant to amoxicillin. This percentage is higher than those 
obtains in developed countries like France (Golstein, 2000) and United State 
of America (Mathai et al., 2001). In developing countries like Dakar, high 
resistance level to antibiotics was observed (Seck, 2005). The drug resulting 
from the association amoxicillin+clavulanic acid was not efficient on E. coli 
strains isolated from urinary tract infections (61.33 % of resistance). These 
observations remain bigger than the 40 % of resistant strains recorded in 
France (Golstein, 2000). The resistance rate (33 %) obtained in this study with 
ceftriaxone is higher than the 5 % observed in Morocco (Fatna et al., 2009) 
and lower than the 43.38 % previously founded in Benin (Ahoyo et al., 2007). 
Thirty-two percent (32 %) of strains isolated were resistance to cefotaxime. 
This resistance percentage is higher than the 3.7 % to 8.8 % obtained 
respectively in United States of America (Mathai et al., 2001) and Senegal 
(Lemort et al., 2006). Relatively, there are high proportions of resistance with 
nalidixic acid (69.75 %), ofloxacin (67.79 %) ciprofloxacin (51.03 %), 
trimethoprim/sulphamid (93.37 %) and chloramphenicol (66.89 %). The 
increase of these resistance levels in developing countries can be attributed to 
many factors such as the poor quality of drugs and/or inadequate dosage, 
long-term treatment, misuse of antibiotics by health professionals and poor 
sanitation (Tandé et al., 2012). The misuse and often uncontrolled antibiotic 
self-medication are addition selection pressure to select resistance strains in 
bacteria. In a previous study, Van der Starre et al. (2010) had found that all 
E. coli strains isolated from urinary tract infections patients who were treated 
inappropriately with ciprofloxacin, were resistant to ciprofloxacin. In 
addition, Wang et al. (2009) have found that the E. coli strains isolated from 
Respiratory Tract Infections samples were resistant to ciprofloxacin (71.8 %) 
and ofloxacin (63.8 %). In fact, many cases of multidrug-resistant bacteria 
have been reported in Benin (Sina et al., 2011), Ivory Coast (Akoua-Koffi et 
al., 2004) and in other sub-Saharan Africa countries (Akinyemi et al., 2005). 
All E. coli ESBL strains isolated in this study were resistant to amoxicillin, 
cefotaxime and ceftriaxone. The emergence of producing Enterobacteria 
ESBL is reported to be a major problem in the treatment of nosocomial 
infections (Camara et al., 2013). 
Among the 16 tested antibiotics, the most efficient was imipenem and 
more than 99 % of E. coli strains isolated were sensitive. These results can be 
explained by the fact that this antibiotic is a β-lactam class of carbapenem. 
This class is known to be resistant to β-lactamases (carbapenemases) 
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hydrolysis (Therrien, 1998). In addition, imipenem is the most sensitive 
carbapenem for the detection of carbapenemases strains producers (Dahmen 
et al., 2012). However, some cases of resistance to imipenem had recently 
been described (Lee et al., 2012; Dash et al., 2013). The strains resistance to 
nitofurantoïn was low (15.15 %). This result is higher than 9.8 % obtained at 
India (Ferron, 1994) on E. coli strains isolated from urinary tract infections. 
These results confirm the effectiveness of this antibiotic in urinary infections 
treatment (McOsker et Fitzpatrick, 1994). The Nitrofurantoin is indicated 
only for the treatment of acute cystitis. The therapeutic doses have a 
bactericidal activity against E. coli isolated from urine (Hooper, 2000; Calbo 
et al., 2006). The resistances observe in our study may be due to the increases 
production of penicillinase and extended-spectrum β-lactamases.  
The research of genes encoding for ESBL production on E. coli strains 
reveals that blaTEM gene was carried by all strains but only 30 % harbored 
bla
SHV
 gene. Our results are higher than 60 % of bla
TEM
 reported in Spain 
(Sanders et Sanders, 1992). These results confirm those of the susceptibility 
testing displaying that all E. coli strains were resistant to penicillinase and 
third generation cephalosporins (cefoxitin, cefuroxime, cefotaxime and 
ceftriaxone) (Livermore, 1995). In other cases, the results of Ahoyo et al. 
(2007) displays 25 % strains carrying the gene bla
TEM
 and 56.25 % also 
harbored the bla
SHV
 gene. African strains possess bla
SHV
 gene (Gangoué-
Piéboji et al., 2005) and the strains producing ESBL currently have genetic 
mutation of β-lactamases (TEM and SHV) (Rakotonirina et al., 2013; 
Philippon, 2013). 
 
Conclusion 
Urinary tract infections are major public health problem. The study 
updates the information about E. coli strains isolated from urinary tract 
infections in Benin. Our data reveals high prevalence of multidrug-resistant 
E. coli strains producing ESBL among no hospitalized patients. Thus, it is 
necessary to avoid prescribing antimicrobial agent treatment to patients 
before pathogen agent identification. The study took into account only strains 
isolated from urinary tract infections. It will be important to extend future 
studies on E. coli strains isolated from other samples. 
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